Gossamer Bio (GOSS) Options Trading Volume Hits 36,131 Contracts, 73.1% of Average Daily Volume
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy GOSS?
Source: NASDAQ.COM
- Active Options Trading: Gossamer Bio Inc (GOSS) recorded an options trading volume of 36,131 contracts today, equivalent to approximately 3.6 million shares, representing 73.1% of its average daily trading volume of 4.9 million shares over the past month, indicating strong market interest in its future performance.
- Put Options Highlighted: Notably, the $2 strike put option expiring on February 20, 2026, saw a significant volume of 12,338 contracts traded today, representing about 1.2 million underlying shares, reflecting investor expectations regarding potential downside risks for GOSS's stock price.
- Novanta Options Activity: Concurrently, Novanta Inc (NOVT) experienced an options trading volume of 3,468 contracts, equivalent to approximately 346,800 shares, which accounts for 72.7% of its average daily trading volume of 476,875 shares over the past month, showcasing ongoing market interest in its stock.
- Call Options Trading: Within NOVT's trading, the $140 strike call option expiring on February 20, 2026, stood out with a trading volume of 1,724 contracts today, representing around 172,400 underlying shares, indicating investor optimism regarding its future price potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.327
Low
10.00
Averages
12.33
High
15.00
Current: 0.327
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit due to its February 23, 2026 announcement that the Phase 3 PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting a severe loss of investor confidence in the company's future prospects, which may jeopardize its listing status on Nasdaq.
- Investor Losses: Hagens Berman law firm is urging investors who suffered significant losses during the class period to submit their claims, suggesting that this event could trigger widespread investor compensation claims, further impacting the company's financial health.
- Regulatory Scrutiny: The lawsuit alleges improper disclosures regarding trial design and patient recruitment, potentially leading to increased regulatory scrutiny, which could affect the company's future financing and market credibility.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, aiming to recover damages for investors who purchased securities between June 16, 2025, and February 20, 2026, highlighting potential violations of federal securities laws.
- False Statements Allegation: The complaint alleges that Gossamer Bio concealed significant adverse facts regarding the design of its PROSERA study while promoting positive results, resulting in artificially inflated stock prices that led investors to buy shares at inflated levels.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, indicating that the lawsuit provides an opportunity for recovery of losses without requiring lead plaintiff status to share in any potential recovery.
- Legal Fee Arrangement: The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees from the court if they successfully recover losses, thereby reducing the financial burden on investors.
See More
Gossamer Bio Investors Class Action Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 1, 2026, to participate in the class action against Gossamer Bio, involving those who purchased securities between June 16, 2025, and February 20, 2026, highlighting the urgency of legal action.
- Study Failure Announcement: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study for pulmonary arterial hypertension failed to meet its primary endpoint, resulting in an 80.3% drop in stock price, which significantly harmed investors and underscored the company's clinical trial risks.
- False Statements Allegation: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose the lower-risk characteristics of Latin American patients, which misled investors about the company's prospects and exacerbated their losses.
- Legal Consultation Access: Investors seeking more information or wishing to participate in the lawsuit can contact Glancy Prongay Wolke & Rotter LLP for legal support and consultation, ensuring their rights are protected.
See More
Reminder for Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, or risk losing their representation in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Gossamer Bio provided overly optimistic statements regarding its Phase 3 PROSERA study while concealing significant adverse facts about the study design, leading to investor losses when the truth emerged, potentially impacting the company's reputation and future financing capabilities.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases, thereby enhancing investor confidence in their representation.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, with the lawsuit covering the period from June 16, 2025, to February 20, 2026, highlighting significant investor dissatisfaction with the company's transparency.
- Stock Price Plunge: Following the trial results announcement, Gossamer's stock plummeted by 80%, which not only undermined investor confidence but also prompted investigations by shareholder rights firms like Hagens Berman, potentially impacting the company's future financing capabilities.
- Trial Design Issues: The lawsuit alleges that Gossamer misrepresented the design of the PROSERA trial, including patient recruitment and site monitoring, as management previously touted the drug as a potential first-in-class therapy, failing to disclose critical trial flaws.
- Nasdaq Compliance Risk: On April 9, 2026, Gossamer revealed that since February 24, 2026, it has not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market, raising concerns about delisting and exacerbating investor anxiety.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026, for participation.
- False Statements Allegation: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering the company's public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests and providing support for potential legal actions.
See More
Gossamer Bio Faces Securities Class Action Lawsuit
- Lawsuit Background: Gossamer Bio, Inc. is facing a securities class action lawsuit due to its February 23, 2026 announcement that the Phase 3 PROSERA study failed to meet its primary endpoint, involving investors from June 16, 2025, to February 20, 2026, indicating potential missteps in clinical trial design.
- Stock Price Plunge: Following the lawsuit announcement, Gossamer's stock price plummeted by 80%, reflecting a severe loss of investor confidence in the company's future prospects, which may jeopardize its listing status on Nasdaq.
- Investor Losses: Hagens Berman law firm is urging investors who suffered significant losses during the class period to submit their claims, suggesting that this event could trigger widespread investor compensation claims, further impacting the company's financial health.
- Regulatory Scrutiny: The lawsuit alleges improper disclosures regarding trial design and patient recruitment, potentially leading to increased regulatory scrutiny, which could affect the company's future financing and market credibility.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, aiming to recover damages for investors who purchased securities between June 16, 2025, and February 20, 2026, highlighting potential violations of federal securities laws.
- False Statements Allegation: The complaint alleges that Gossamer Bio concealed significant adverse facts regarding the design of its PROSERA study while promoting positive results, resulting in artificially inflated stock prices that led investors to buy shares at inflated levels.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, indicating that the lawsuit provides an opportunity for recovery of losses without requiring lead plaintiff status to share in any potential recovery.
- Legal Fee Arrangement: The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees from the court if they successfully recover losses, thereby reducing the financial burden on investors.
See More
Gossamer Bio Investors Class Action Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 1, 2026, to participate in the class action against Gossamer Bio, involving those who purchased securities between June 16, 2025, and February 20, 2026, highlighting the urgency of legal action.
- Study Failure Announcement: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study for pulmonary arterial hypertension failed to meet its primary endpoint, resulting in an 80.3% drop in stock price, which significantly harmed investors and underscored the company's clinical trial risks.
- False Statements Allegation: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose the lower-risk characteristics of Latin American patients, which misled investors about the company's prospects and exacerbated their losses.
- Legal Consultation Access: Investors seeking more information or wishing to participate in the lawsuit can contact Glancy Prongay Wolke & Rotter LLP for legal support and consultation, ensuring their rights are protected.
See More
Reminder for Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, or risk losing their representation in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Gossamer Bio provided overly optimistic statements regarding its Phase 3 PROSERA study while concealing significant adverse facts about the study design, leading to investor losses when the truth emerged, potentially impacting the company's reputation and future financing capabilities.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases, thereby enhancing investor confidence in their representation.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, with the lawsuit covering the period from June 16, 2025, to February 20, 2026, highlighting significant investor dissatisfaction with the company's transparency.
- Stock Price Plunge: Following the trial results announcement, Gossamer's stock plummeted by 80%, which not only undermined investor confidence but also prompted investigations by shareholder rights firms like Hagens Berman, potentially impacting the company's future financing capabilities.
- Trial Design Issues: The lawsuit alleges that Gossamer misrepresented the design of the PROSERA trial, including patient recruitment and site monitoring, as management previously touted the drug as a potential first-in-class therapy, failing to disclose critical trial flaws.
- Nasdaq Compliance Risk: On April 9, 2026, Gossamer revealed that since February 24, 2026, it has not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market, raising concerns about delisting and exacerbating investor anxiety.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026, for participation.
- False Statements Allegation: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning controls for placebo response at certain testing sites, rendering the company's public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests and providing support for potential legal actions.
See More
